Trans-pulmonary Biomarkers in Pulmonary Hypertension
NCT01961232 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 100
Last updated 2026-03-17
Summary
The investigators are testing whether the addition of Pulmonary Hypertension-related biomarkers, measured across the pulmonary circulation, to the standard hemodynamic evaluation for Pulmonary Hypertension will lead to more informed choices of Pulmonary Hypertension therapy and improved patient outcomes.
Conditions
- Pulmonary Hypertension
Sponsors & Collaborators
- collaborator INDUSTRY
-
Vanderbilt University
lead OTHER
Principal Investigators
-
Ken Monahan, MD · Vanderbilt University Medical Center
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2013-08-31
- Primary Completion
- 2015-01-31
- Completion
- 2027-06-30
Countries
- United States
Study Locations
More Related Trials
-
Bioenergetic Effect of Pioglitazone in CLD-PH
NCT06336798 ·Status: RECRUITING ·Phase: PHASE2
-
Novel Index (PIMR) in PAH
NCT05812976 ·Status: COMPLETED
-
Hormonal, Metabolic, and Signaling Interactions in PAH
NCT01884051 ·Status: RECRUITING
-
Neuromodulation in Patients With Pulmonary Arterial Hypertension
NCT06802380 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
Tamoxifen Therapy to Treat Pulmonary Arterial Hypertension
NCT03528902 ·Status: COMPLETED ·Phase: PHASE2
-
Pulmonary Hypertension and Imatinib
NCT01092897 ·Status: COMPLETED
-
Telemonitoring to Treat Group 2 Pulmonary Hypertension
NCT04882774 ·Status: WITHDRAWN ·Phase: PHASE2
-
Genetic and Environmental Characteristics of Primary Pulmonary Hypertension
NCT00091546 ·Status: COMPLETED
-
Pharmacogenomics in Pulmonary Arterial Hypertension
NCT00593905 ·Status: WITHDRAWN
-
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess Safety and Efficacy of Ambrisentan in Subjects With Pulmonary Arterial Hypertension.
NCT00423202 ·Status: COMPLETED ·Phase: PHASE3
-
Endothelial Function in Patients With Pulmonary Arterial Hypertension
NCT01317134 ·Status: COMPLETED ·Phase: NA
-
A Study on the Efficacy and Safety of Empagliflozin in the Treatment of Pulmonary Arterial Hypertension
NCT06554301 ·Status: RECRUITING ·Phase: PHASE1
-
Real World Observational Study of Sotatercept for Pulmonary Hypertension
NCT06751082 ·Status: RECRUITING
-
Effect of CS1 in Subjects With Pulmonary Arterial Hypertension
NCT05224531 ·Status: COMPLETED ·Phase: PHASE2
-
Inhaled Nitrite in Subjects With Pulmonary Hypertension
NCT01431313 ·Status: COMPLETED ·Phase: PHASE2
-
Safety of SonoVue on Pulmonary Hemodynamics
NCT01306292 ·Status: COMPLETED ·Phase: PHASE2
-
Pulmonary Vascular Disease Phenomics Program PVDOMICS
NCT02980887 ·Status: ACTIVE_NOT_RECRUITING
-
Targeting Right Ventricle in Pulmonary Hypertension Gilead
NCT02829034 ·Status: COMPLETED ·Phase: PHASE4
-
A Randomized Trial of Udenafil Therapy in Patients With Mild Pulmonary Hypertension [ULTIMATE-Mild PHT]
NCT01696240 ·Status: UNKNOWN ·Phase: PHASE3
-
rhBNP in Type 3 Pulmonary Hypertension
NCT05716984 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE4
-
A Study to Evaluate the Efficacy, Safety and Tolerability of PDNO Infusion in Patients With Pulmonary Hypertension After Cardiopulmonary Bypass Surgery
NCT05699486 ·Status: UNKNOWN ·Phase: PHASE2
-
The Prevalence of Pulmonary Hypertension in Patients With COVID-19.
NCT04459364 ·Status: COMPLETED
-
Cardiopulmonary Function Assessment and NO-Based Therapies for Patients With Hemolysis-Associated Pulmonary Hypertension
NCT00352430 ·Status: COMPLETED ·Phase: PHASE1
-
6R-BH4 Pulmonary Arterial Hypertension Study
NCT00435331 ·Status: COMPLETED ·Phase: PHASE1
-
Pulmonary Hypertension Screening in Patients With Interstitial Lung Disease for Earlier Detection
NCT05776225 ·Status: ACTIVE_NOT_RECRUITING